T-Cell Vaccination in Multiple Sclerosis (MS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00220428|
Recruitment Status : Unknown
Verified January 2007 by Sheba Medical Center.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : January 24, 2007
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Biological: T-Cell Vaccination||Phase 1 Phase 2|
Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones.
Clinical immunologic and neuroradiologic evaluation.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial|
|Study Start Date :||July 1998|
|Study Completion Date :||December 2007|
- safety assessment of T-cell vaccination in nonresponding MS patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00220428
|Contact: Anat Achiron, MD PhD||972-3-5303932||ACHIRON@POST.TAU.AC.IL|
|Contact: Matilda Mandel, MD||972-3-5305309|
|Multiple Sclerosis Center||Recruiting|
|Ramat Gan, Israel|
|Contact: Anat Achiron, MD PhD 972-3-5303932 Achiron@post.tau.ac.il|
|Contact: Matilda Mandel, MD 972-3-5304081|
|Principal Investigator: Anat Achiron, MD PhD|
|Principal Investigator:||Anat Achiron, MD PhD||Sackler School of Medicine|